Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma

Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Ethan Basch, Bryce B. Reeve, Sandra A. Mitchell et al. · JNCI Journal of the National Cancer Institute · 2014 · 1.1K citations · Full text

Pharmacy, Oncology, Cancer Control +15

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

Patrick J. Loehrer, Yang Feng, Higinia R. Cárdenes et al. · Journal of Clinical Oncology · 2011 · 832 citations

Medicine, Oncology, Chemotherapy +7

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

Bruno Chauffert, F. Mornex, F. Bonnetain et al. · Annals of Oncology · 2008 · 694 citations

Medicine, Oncology, Radiation Oncology +15

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

F. Huguet, Thierry André, Pascal Hammel et al. · Journal of Clinical Oncology · 2007 · 536 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer

Albert C. Koong, Quynh‐Thu Le, Anthony D. Ho et al. · International Journal of Radiation Oncology*Biology*Physics · 2004 · 446 citations

Medicine, Oncology, Radiation Oncology +13